指南与共识脑血管病

儿童癌症幸存者颅脑照射后卒中风险管理的共识建议:一项德尔菲研究

Consensus Recommendations for Managing Childhood Cancer Survivors at Risk for Stroke After Cranial Irradiation: A Delphi Study.
指南 / 共识 · Neurology · 2022-08-17

针对因中枢神经系统肿瘤或其他累及中枢神经系统的儿童癌症而接受颅脑照射的儿童癌症幸存者(CCS),现有证据不足以支持卒中预防指南。研究采用德尔菲法,咨询来自美国/加拿大的45名多学科医生,经过三轮匿名情景问卷,就卒中筛查与管理实践达成共识或明确争议领域。专家组就神经科转诊指征和可干预脑血管病危险因素实验室筛查达成共识,阿司匹林治疗决策在神经影像正常时共识不推荐,异常时多交由专科医生决定。

要点

  • 专家组就神经科转诊指征及可干预脑血管病危险因素实验室筛查在多数情景下达成共识。
  • 神经影像正常时,专家组共识不推荐阿司匹林治疗(86%同意)。
  • 无既往出血证据的海绵状血管瘤,几乎均同意不使用阿司匹林(93%)。

核心结论

  • 尽管缺乏证据指导有卒中风险的CCS管理,通过共识方法制定的专家建议和理由有助于支持临床决策。

研究设计与样本

  • 采用德尔菲法,咨询来自美国/加拿大的45名在CCS方面具有专长的多学科医生,进行三轮迭代的匿名情景问卷,基于专家组成员的汇总应答,以达成共识(≥90%同意)、一致(89%-70%同意)或理解分歧理由(<70%同意)。

主要发现

  • 全部45名医生参与了前两轮,44名参与了第三轮。
  • 专家组就多数情景下转诊神经科的指征和可干预脑血管病危险因素的实验室筛查达成共识。
  • 神经影像正常情景下,86%同意不推荐阿司匹林治疗。
  • 无既往出血证据的海绵状血管瘤,93%同意不使用阿司匹林;大血管脑血管病,93%同意使用阿司匹林;小血管脑血管病且有既往卒中证据,86%同意使用阿司匹林。
  • 仍存在争议(同意率低于70%)的临床决策包括:对无症状CCS进行神经影像筛查脑血管病、因海绵状血管瘤转诊神经科、海绵状血管瘤伴既往出血时使用阿司匹林、小血管脑血管病且无既往卒中时使用阿司匹林以及他汀类药物的指征。

关键数值与推荐

  • 共识定义为≥90%同意;一致定义为89%-70%同意;分歧定义为<70%同意。
  • 神经影像正常时,86%同意不推荐阿司匹林治疗。
  • 无既往出血证据的海绵状血管瘤,93%同意不使用阿司匹林。
  • 大血管脑血管病,93%同意使用阿司匹林。
  • 小血管脑血管病且有既往卒中证据,86%同意使用阿司匹林。

临床怎么用

  • 神经影像正常时,专家组共识不推荐阿司匹林治疗。
  • 无既往出血证据的海绵状血管瘤,专家组几乎均同意不使用阿司匹林。
  • 大血管脑血管病,专家组几乎均同意使用阿司匹林;小血管脑血管病且有既往卒中证据,86%同意使用阿司匹林。
  • 神经影像异常情景下的阿司匹林治疗决策交由专科医生决定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: There is insufficient evidence to support stroke prevention guidelines for childhood cancer survivors (CCS) treated with cranial irradiation for CNS tumors or other childhood cancers involving the CNS. We used a systematic consensus-building methodology to develop expert recommendations and define areas of controversy in managing asymptomatic CCS at risk for stroke. METHODS: A Delphi process was used to query a multispecialty panel of 45 physicians from the United States/Canada, with expertise in CCS, about their stroke screening and management practices (imaging, referrals, laboratory testing, and medications). Three iterative rounds of anonymous, scenario-based questionnaires, building on panelists' aggregate responses, were used to reach consensus (≥90% agreement), agreement (89%-70% agree), or to understand the rationale for disagreement (<70% agree). RESULTS: All 45 physicians participated in the first 2 rounds and 44 in the third. Panelists reached consensus on indications for referral to neurology and laboratory screening for modifiable cerebral vascular disease (CVD) risk factors in most scenarios. Panelists agreed that aspirin therapy is not recommended in the scenario of normal neuroimaging (86% agreed). Decisions about aspirin therapy in scenarios with abnormal neuroimaging were deferred to specialists; almost all agreed with not using aspirin for cavernomas with no evidence for previous hemorrhage (93%) and using aspirin for both large vessel CVD (93%) and small vessel CVD with evidence of previous stroke (86%). Clinical decisions that remain controversial (less than 70% agreement) include neuroimaging to screen asymptomatic CCS for CVD, referral to neurology for cavernomas, aspirin use in the setting of cavernomas with previous hemorrhage, or with evidence for small vessel CVD and no previous stroke, and indications for statins. Overall, pediatric neurologists/neuro-oncologists and radiation oncologists were more likely to advocate for screening and interventions. DISCUSSION: Despite lack of evidence to guide the management of CCS at risk for stroke, expert recommendations and rationale developed by consensus methodology are helpful to support clinical decision-making.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kenney LB, Ames BL, Huang MS, et al. Consensus Recommendations for Managing Childhood Cancer Survivors at Risk for Stroke After Cranial Irradiation: A Delphi Study. Neurology. 2022. PMID: 35977833. doi:10.1212/WNL.0000000000201014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。